Education
About Us
Working with TipRanks
Follow Us
Lantheus (DE:0L8)
FRANKFURT:0L8
0L8 Stock Chart & Stats
€65.72
€2.80(3.09%)
At close: 4:00 PM EST
€65.72
€2.80(3.09%)
Day’s Range― - ―
52-Week Range€41.91 - €100.25
Previous CloseN/A
Volume0.00
Average Volume (3M)17.00
Market Cap
€4.45B
Enterprise Value€5.75B
Total Cash (Recent Filing)€359.12M
Total Debt (Recent Filing)€673.25M
Price to Earnings (P/E)19.2
Beta0.28
Next Earnings
Apr 30, 2026EPS Estimate
1.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.45
Shares Outstanding64,605,896
10 Day Avg. Volume23
30 Day Avg. Volume17
Financial Highlights & Ratios
PEG Ratio-0.82
Price to Book (P/B)4.12
Price to Sales (P/S)2.91
P/FCF Ratio12.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€73.19Price Target Upside11.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)4.47
Revenue Forecast (FY)€1.25B
Bulls Say, Bears Say
Bulls Say
Product Launches And Market ExpansionAnalyst highlights that the launch of a new diagnostic and wider use of PET imaging for Alzheimer’s disease can reinvigorate top-line growth and diversify revenue exposure beyond therapeutics.
Regulatory ApprovalsAnalyst notes pending regulatory decisions for new diagnostic agents that may expand addressable markets and support future revenue growth if approvals are obtained.
Reimbursement PositioningAnalyst expects a next-generation formulation to gain transitional pass-through reimbursement, which could stabilize flagship product sales as a competitor's preferential status expires.
Bears Say
Leadership UncertaintyMultiple leadership departures, including the President and COO, introduce uncertainty around strategic execution and may weigh on investor confidence during the transition.
Pricing Pressure And Volume TrendsManagement identified ongoing pricing pressure and declines in imaging dose volumes that are likely to suppress near-term revenue and contribute to share price volatility.
Weak Near-term GuidanceAnalyst warns that guidance below consensus and delayed benefits from new product formulations push recovery into later periods, increasing execution risk for the company.
Lantheus News
0L8 FAQ
What was Lantheus’s price range in the past 12 months?
Lantheus lowest stock price was €41.91 and its highest was €100.25 in the past 12 months.
What is Lantheus’s market cap?
Lantheus’s market cap is €4.45B.
When is Lantheus’s upcoming earnings report date?
Lantheus’s upcoming earnings report date is Apr 30, 2026 which is in 51 days.
How were Lantheus’s earnings last quarter?
Lantheus released its earnings results on Feb 26, 2026. The company reported €1.451 earnings per share for the quarter, beating the consensus estimate of €1.037 by €0.413.
Is Lantheus overvalued?
According to Wall Street analysts Lantheus’s price is currently Undervalued.
Does Lantheus pay dividends?
Lantheus does not currently pay dividends.
What is Lantheus’s EPS estimate?
Lantheus’s EPS estimate is 1.07.
How many shares outstanding does Lantheus have?
Lantheus has 64,605,896 shares outstanding.
What happened to Lantheus’s price movement after its last earnings report?
Lantheus reported an EPS of €1.451 in its last earnings report, beating expectations of €1.037. Following the earnings report the stock price went up 2.462%.
Which hedge fund is a major shareholder of Lantheus?
Currently, no hedge funds are holding shares in DE:0L8
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lantheus Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€73.19 (11.37% Upside)
€73.19 (11.37% Upside)
Blogger Sentiment
Bullish
DE:0L8 Sentiment 100%
Sector Average 70%
Sector Average 70%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-27.60%
12-Months-Change
Fundamentals
Return on Equity
20.58%
Trailing 12-Months
Asset Growth
10.53%
Trailing 12-Months
Company Description
Lantheus
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.
0L8 Company Deck
0L8 Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
Balanced / Neutral: The call highlighted meaningful strategic progress — acquisitions (Neuraceq, OCTEVY candidate), a broadened radiodiagnostic pipeline, strong product positions (PYLARIFY volumes, DEFINITY market share), multiple near-term regulatory milestones, and a clear commercialization plan targeting 2027 growth. However, near-term pressures are material: PYLARIFY revenue decline and pricing headwinds, gross margin compression (~289 bps YoY), Q4 cash-flow and free-cash-flow deterioration, and notable one-time integration and litigation costs. Management is taking prudent, deliberate steps (divestiture of SPECT, focusing capital on diagnostics, launch-readiness investments) which support a constructive medium-to-long-term outlook, but the near-term financial headwinds and execution/timing risks balance the positives.View all DE:0L8 earnings summaries0L8 Revenue Breakdown
65.91% Radiopharmaceutical oncology
30.09% Precision diagnostics
4.00% Strategic Partnerships and other revenue
0L8 Stock 12 Month Forecast
Average Price Target
€73.19
▲(11.37% Upside)
Technical Analysis
Perrigo Company
―
Supernus Pharmaceuticals
―
ANI Pharmaceuticals
―
HUTCHMED
―
Amneal Pharmaceuticals
―